Home » Stocks » ARQT

Arcutis Biotherapeutics, Inc. (ARQT)

Stock Price: $30.57 USD 0.31 (1.02%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Market Cap 1.47B
Revenue (ttm) n/a
Net Income (ttm) -135.68M
Shares Out 50.08M
EPS (ttm) -10.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $30.57
Previous Close $30.26
Change ($) 0.31
Change (%) 1.02%
Day's Open 30.14
Day's Range 29.90 - 31.97
Day's Volume 170,534
52-Week Range 17.51 - 39.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Presentations will highlight new data on the safety, efficacy, and tolerability of once-daily, topical roflumilast cream for the treatment of chronic, mild-to-severe plaque psoriasis as well as once-dai...

3 days ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

1 week ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., March 26, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

3 weeks ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

1 month ago - GlobeNewsWire

Poster presentations highlight new data for roflumilast cream, including long-term safety and efficacy results in adults with chronic plaque psoriasis Poster presentations highlight new data for roflumi...

1 month ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

1 month ago - GlobeNewsWire

Arcutis Biotherapeutics, Inc. (ARQT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

WESTLAKE VILLAGE, Calif,, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

2 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

2 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated...

2 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

3 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated...

3 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

3 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

4 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

4 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

4 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

4 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

4 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

4 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

5 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated...

5 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

5 months ago - GlobeNewsWire

Arcutis has an upcoming phase 3 data readout catalyst in 1Q 2021. Past data has been good, with a clear competitive difference.

5 months ago - Seeking Alpha

WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

5 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated...

5 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

6 months ago - GlobeNewsWire

The company announced the pricing of a public offering of common stock.

6 months ago - The Motley Fool

WESTLAKE VILLAGE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

6 months ago - GlobeNewsWire

Any time there is good news that drives a stock higher, some investors know that the companies making the news may use the strength to raise additional capital. Not all secondary offerings come on the h...

Other stocks mentioned: CRDF, FCEL, IMXI, LAD, OMI
6 months ago - 24/7 Wall Street

WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments f...

6 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments f...

6 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ((Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments ...

7 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments f...

7 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments f...

7 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

8 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

8 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

8 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

8 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

8 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

8 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

9 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediat...

9 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

10 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

10 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo...

10 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

10 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

11 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments f...

11 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments f...

1 year ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments f...

1 year ago - GlobeNewsWire

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2020
Stock Exchange
NASDAQ
Ticker Symbol
ARQT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price forecast is 56.83, which is an increase of 85.90% from the latest price.

Price Target
$56.83
(85.90% upside)
Analyst Consensus: Strong Buy